Patents by Inventor Paul Andrew Jamieson

Paul Andrew Jamieson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sublingual administration of statins
    Patent number: 9849083
    Abstract: The invention provides a pharmaceutical composition for the transmucosal delivery of a statin, said composition comprising a statin and a carrier in which said statin is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a statin for use in inhibiting cholesterol synthesis in vivo, where in said use said composition is delivered by the transmucosal route.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: December 26, 2017
    Assignee: LondonPharma Ltd.
    Inventors: Martin James Sams, Juliet Victoria High, Paul Andrew Jamieson, Clive Booles
  • Sublingual Administration of Statins
    Publication number: 20150328142
    Abstract: The invention provides a pharmaceutical composition for the transmucosal delivery of a statin, said composition comprising a statin and a carrier in which said statin is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a statin for use in inhibiting cholesterol synthesis in vivo, where in said use said composition is delivered by the transmucosal route.
    Type: Application
    Filed: December 14, 2012
    Publication date: November 19, 2015
    Applicant: LondonPharma Ltd.
    Inventors: Martin James Sams, Juliet Victoria High, Paul Andrew Jamieson, Clive Booles
  • Drug Delivery Technology
    Publication number: 20150005307
    Abstract: The invention provides a pharmaceutical composition for the transmucosal delivery of a PDE5 inhibitor, said composition comprising a PDE5 inhibitor and a carrier in which said PDE5 inhibitor is soluble or forms a suspension or emulsion. The invention also provides a pharmaceutical composition comprising a PDE5 inhibitor for use in inhibiting PDE activity in vivo, where in said use said composition is delivered by the transmucosal route.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 1, 2015
    Applicant: LondonPharma Ltd.
    Inventors: Martin James Sams, Juliet Victoria High, Paul Andrew Jamieson, Clive Booles